Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer (ANZUP1304).

See ANZCTR for full trial details >

 

Trial Summary:

To determine the effectiveness of enzalutamide versus a conventional NSAA, when combined with a lutenising hormone releasing hormone analogue (LHRHA) or surgical castration, as first line androgen deprivation therapy.

Supported By:

Astellas Scientific and Medical Affairs Inc.

Eligibility:

Men (≥ 18 years) with metastatic prostate cancer commencing androgen deprivation therapy.

Registration ID:

ACTRN12614000110684

Participation:

International

Australian Lead Group:

ANZUP

Status:

Follow-Up

Activation Date:

28/03/2014

Chairs:

Prof Ian Davis and Prof Christopher Sweeney

Contact:

ENZAMET@ctc.usyd.edu.au